Vera Therapeutics Stuck in a Bull‑High‑Vol Cycle After a Historic Drawdown

Why the lingering volatility may temper upside despite recent rally

VERA Vera Therapeutics, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Vera Therapeutics, Inc. (VERA) — Return Performance

Vera Therapeutics delivered a mixed return profile over the past five years, posting strong long‑term gains but significant recent weakness. While the 5‑year total return was +143.5% (alpha versus sector ETF of +71.7%), the most recent 1‑month and 3‑month periods were down –9.09% and –19.74%, respectively, underperforming both its own historical average and the XLV sector by roughly 2–3 percentage points each month.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

VERA

The stock generated positive alpha over longer horizons, achieving +101.2% versus a 35.3% sector outperformance for the 3‑year window and +37.1% versus 22.5% for the trailing year. However, short‑term momentum reversed sharply, with the past 6‑month return of –36.2% lagging its sector by about 1 percentage point, indicating a divergence between recent price weakness and the longer‑run upside trend.

Returns Overview

Vera Therapeutics, Inc. (VERA) — Return Charts

Volatility Analysis

Vera Therapeutics, Inc. (VERA) — Volatility Profile

Vera Therapeutics exhibits markedly elevated price variability relative to the broader market, with an annualized volatility of 91.5%—over five times the S&P 500’s 17.8%. This heightened turbulence translates into a pronounced downside risk profile: the downside deviation stands at 63.5%, and the historical maximum drawdown reached -84.9% over a 13‑month decline from November 2021 to January 2023, underscoring severe loss potential during adverse market regimes. While recent short‑term volatility (54.9% over 60 days) remains below the long‑term annualized figure, it still exceeds the 252‑day rolling volatility of 63.4%, indicating a modest tapering but nonetheless persistent risk exposure.

Volatility Metrics

VERA

The company’s volatility is substantially higher than the S&P 500 benchmark, reflecting its biotech sector sensitivity and limited operating history. Downside deviation of 63.5% signals that negative returns are more extreme than the overall market’s typical fluctuations, and the -84.9% max drawdown illustrates a deep, prolonged loss episode lasting over a year, which can erode investor confidence. The 60‑day volatility of 54.9% is lower than the 252‑day level of 63.4%, suggesting a short‑term easing of price swings but still far above market norms, implying that risk remains elevated even as momentum moderates.

Annualized volatility of Vera Therapeutics (91.5%) is more than five times the S&P 500’s 17.8%.
Downside deviation of 63.5% indicates a strong bias toward larger negative moves compared with the market.
Maximum historical drawdown of -84.9% reflects severe loss potential and a prolonged recovery period.
Short‑term (60‑day) volatility has eased to 54.9%, yet remains above long‑term average and market benchmarks.
Even the 252‑day rolling volatility (63.4%) is still considerably higher than the S&P 500, confirming sustained risk.

Positive Characteristics
Recent decline in short‑term volatility suggests a possible stabilization of price swings.
The recovery milestone reached on 2024‑01‑31 indicates that the stock has begun to regain lost ground after its deep drawdown.

Volatility Analysis

Vera Therapeutics, Inc. (VERA) — Volatility & Drawdown Charts

Beta & Correlation

Vera Therapeutics, Inc. (VERA) — Beta Profile

Vera Therapeutics exhibits a trailing beta of 1.148 versus the S&P 500, placing it in the market‑like range (0.8‑1.2). This indicates that, on average, the stock moves roughly in line with broad equity markets but carries modestly higher volatility. The upside beta of 0.986 is slightly below the overall beta, while the downside beta of 1.096 exceeds it, revealing a tilt toward larger losses during market declines—a key asymmetry for risk‑averse investors. The low R-squared of 4.5% and correlation of 0.211 with the S&P 500 suggest that only a small fraction of Vera’s price movement is explained by overall market dynamics; the majority (95.5%) is idiosyncratic. When measured against its sector benchmark, XLV, the sector beta of 1.074 remains close to the market beta, but the sector correlation drops further to 0.173 with an R² of just 3%. This decomposition shows that Vera’s risk profile is driven more by company‑specific factors than by sector trends, offering potential diversification benefits for a portfolio heavily weighted in healthcare.

Beta & Correlation Metrics

VERA

The trailing beta of 1.148 signals that Vera Therapeutics behaves slightly more aggressively than the market, yet remains within the typical range for equities, implying no extreme leverage exposure. However, the asymmetric beta—downside 1.096 versus upside 0.986—means the stock is more sensitive to market drops, which could amplify losses in bearish periods. With an R-squared of just 4.5%, Vera’s returns are largely driven by idiosyncratic factors rather than systematic market movements, underscoring the importance of company‑specific analysis. The sector beta of 1.074 indicates that sector dynamics contribute modestly to its risk, but the low sector correlation (0.173) and R² (3%) reaffirm that sector exposure is a minor component relative to firm‑level drivers.

Trailing beta of 1.148 places Vera in the market‑like range, indicating modestly higher volatility than the S&P 500.
Downside beta (1.096) exceeds upside beta (0.986), highlighting greater sensitivity to market declines.
R-squared of 4.5% means only a small portion of price movement is explained by overall market trends; 95.5% is idiosyncratic.
Sector beta of 1.074 is close to the market beta, but sector correlation (0.173) and R² (3%) show limited sector‑driven risk.
The systematic vs idiosyncratic split suggests diversification benefits for portfolios seeking exposure outside broad market movements.

Positive Characteristics
Beta remains within the market‑like range, avoiding extreme leverage risk.
Low correlation and R-squared provide strong diversification potential relative to both the S&P 500 and healthcare sector.

Beta & Correlation

Vera Therapeutics, Inc. (VERA) — Rolling Beta

Positive Notes

Beta remains within the market‑like range, avoiding extreme leverage risk.

Low correlation and R-squared provide strong diversification potential relative to both the S&P 500 and healthcare sector.

Risk-Adjusted Returns

Vera Therapeutics, Inc. (VERA) — Risk-Adjusted Performance

Vera Therapeutics, Inc. (VERA) delivers a Sharpe ratio of 0.657, indicating that its risk‑adjusted return falls short of the benchmark threshold of 1.0 for a ‘good’ profile. However, the Sortino ratio of 0.948 exceeds the Sharpe figure, suggesting that VERA’s downside volatility is lower than its total volatility and that the stock has been more efficient at generating returns when adverse price movements are filtered out. The Calmar ratio of 0.751 reflects a moderate return relative to the maximum historical drawdown, while an Information Ratio of 0.57 signals consistent alpha generation above a relevant benchmark. The Treynor ratio of 52.416, expressed in percentage points per unit of systematic risk (beta), underscores that VERA has delivered substantial excess returns for each unit of market exposure.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

VERA

Vera Therapeutics’ Sharpe ratio below 1.0 signals that the stock’s total risk‑adjusted performance is modest, yet the higher Sortino ratio reveals a favorable asymmetry: downside risk has been relatively contained compared with overall volatility. The Calmar ratio of 0.751 indicates that while the company can generate positive returns, its worst drawdown has eroded a notable portion of those gains, implying investors should monitor potential downside spikes. An Information Ratio above 0.5 confirms that active management or company‑specific factors have contributed consistent excess returns, and the elevated Treynor ratio demonstrates strong compensation for systematic market risk.

Sharpe ratio of 0.657 places VERA below the ‘good’ threshold, highlighting limited total risk‑adjusted return.
Sortino ratio (0.948) exceeds Sharpe, indicating a relatively benign downside volatility profile.
Calmar ratio of 0.751 suggests that historical drawdowns have meaningfully trimmed overall returns.
Information Ratio of 0.57 reflects consistent alpha generation above the benchmark.
Treynor ratio of 52.416 shows robust excess return per unit of systematic risk.

Positive Characteristics
Sortino > Sharpe points to a favorable downside risk characteristic.
Information Ratio above 0.5 demonstrates reliable active outperformance.
High Treynor ratio indicates strong compensation for market exposure.

Risk-Adjusted Returns

Vera Therapeutics, Inc. (VERA) — Rolling Sharpe & Sortino

Positive Notes

Sortino > Sharpe points to a favorable downside risk characteristic.

Information Ratio above 0.5 demonstrates reliable active outperformance.

High Treynor ratio indicates strong compensation for market exposure.

Market Regime Analysis

Vera Therapeutics, Inc. (VERA) — Regime Behavior

Vera Therapeutics (VERA) exhibits a stark contrast in performance across market regimes. In bull markets with low volatility the stock has delivered an impressive average monthly return of 15.4% over 25 months, reflecting strong upside momentum when equity sentiment is stable. Conversely, during volatile uptrends (Bull-HighVol) its average return collapses to near‑zero at 0.06%, indicating that heightened market turbulence erodes the company’s growth drivers. In bear environments the stock suffers sharply in orderly declines (Bear-LowVol) with a -22.5% average loss, yet it limits downside during volatile downturns (Bear-HighVol) to only -5.1%, suggesting some defensive resilience when markets are chaotic.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

VERA

The upside capture ratio of 184.2% shows that VERA outperforms the S&P 500 by a wide margin in rising markets, but its downside capture of -8.7% translates to a negative capture ratio of -21.26, meaning losses are amplified relative to market declines in calm bear phases. The current Bull-HighVol regime dampens VERA’s upside potential, as its historical return in this environment is essentially flat, implying that investors should temper expectations for strong gains until volatility subsides. However, the modest loss during Bear‑HighVol suggests a degree of defensive quality when markets are stressed, making VERA relatively less vulnerable in crisis periods.

Market Regime Analysis

Vera Therapeutics, Inc. (VERA) — Regime & Capture Charts

Regime Timeline

VERA thrives in low‑volatility bull markets with >15% average monthly gains.
Performance deteriorates sharply in calm bear markets, delivering -22.5% average loss.
During volatile uptrends the stock’s return is near zero, indicating sensitivity to market turbulence.
Downside capture of -8.7% and negative capture ratio signal amplified losses in orderly declines but limited downside in chaotic bear periods.
Current Bull‑HighVol environment suppresses VERA’s upside despite a high upside capture metric.

Positive Characteristics
High upside capture (184.2%) demonstrates strong participation in market rallies when volatility is low.
Limited loss (-5.1%) in Bear‑HighVol suggests defensive characteristics during crisis-driven selloffs.

Investment Highlights & Risk Summary

Vera Therapeutics, Inc. (VERA) — Summary & Implications

Vera Therapeutics delivered a robust 37.05% total return over the past year, generating an alpha of 18.06% versus the S&P 500 and outpacing its healthcare sector benchmark XLV by 22.53%. The stock’s upside capture of 184.2% indicates strong participation in market rallies, while a downside capture of -8.7% suggests limited sensitivity to market declines; however, this asymmetric profile is tempered by an extreme maximum drawdown of -84.89%, reflecting the potential for severe capital erosion during adverse periods. Volatility remains elevated at an annualized 91.52%, and a beta of 1.148 signals higher systematic risk than the broader market, resulting in a Sharpe ratio of 0.657—below the conventional threshold of 1.0 for attractive risk‑adjusted performance. Investors should weigh the compelling return upside against the pronounced drawdown risk and high volatility when considering Vera Therapeutics for a medium‑term (6‑18 month) horizon.

Summary Dashboard

Investment Highlights

Year‑to‑date total return of 37.05% exceeds both the S&P 500 (+19%) and the healthcare sector XLV (+14%).
Alpha of 18.06% versus the S&P 500 demonstrates that the stock has delivered excess returns after accounting for market movements.
Upside capture of 184.2% shows that Vera participates nearly twice as strongly as the market in bullish phases, while downside capture of -8.7% indicates limited exposure to market declines.
Sector beta of 1.074 and overall beta of 1.148 reflect a modestly higher sensitivity to sector and market swings, offering potential for outperformance when healthcare trends are positive.

Risk-Return Rankings

VERA HIGH

High return potential offset by extreme volatility and deep historical drawdown.

Strength: Strong absolute return and alpha generation (37.05% return, 18.06% alpha).

Concern: Maximum drawdown of -84.89% indicates severe downside risk.

Key Takeaways

Vera Therapeutics has delivered outsized returns relative to both the market and its sector.
The stock’s upside capture exceeds 180%, but this comes with an annualized volatility of over 90%.
A Sharpe ratio of 0.657 suggests modest risk‑adjusted performance; investors should not rely on the high return alone.
Historical drawdown depth (-84.89%) is a red flag for capital preservation, especially in volatile market environments.

PORTFOLIO IMPLICATIONS

Given its high beta and volatility, Vera Therapeutics may serve as an opportunistic satellite position within a diversified healthcare allocation, providing upside potential during sector rallies while contributing limited downside correlation. However, the extreme drawdown history warrants limiting exposure to a modest percentage of portfolio capital and pairing the stock with lower‑volatility, higher‑Sharpe assets to balance overall risk profile.

VERA

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.